Table 3.
Drug‐related adverse events in entire treatment period
| Any grade, n (%) | Grade 3, n (%) | |
|---|---|---|
| Hematological | ||
| Decreased neutrophil count | 9 (100) | 7 (78) |
| Decreased white blood cell count | 9 (100) | 2 (22) |
| Decreased platelet count | 5 (56) | 0 |
| Anemia | 2 (22) | 1 (11) |
| Decreased lymphocyte count | 2 (22) | 0 |
| Non‐hematological | ||
| Pyrexia | 9 (100) | 0 |
| Arthralgia | 9 (100) | 0 |
| Increased ALT level | 8 (89) | 2 (22) |
| Increased AST level | 8 (89) | 2 (22) |
| Injection site reaction (erythema, pruritus, joint pain) | 7 (78) | 0 |
| Chills | 6 (67) | 0 |
| Malaise | 6 (67) | 0 |
| Myalgia | 6 (67) | 0 |
| Fatigue | 5 (56) | 1 (11) |
| Hypertriglyceridemia | 4 (44) | 2 (22) |
| Weight decreased | 4 (44) | 0 |
| Decreased appetite | 4 (44) | 0 |
| Headache | 4 (44) | 0 |
| Alopecia | 4 (44) | 0 |
| Nausea | 3 (33) | 0 |
| Rash | 3 (33) | 0 |
| Retinopathy | 2 (22) | 0 |
| Constipation | 2 (22) | 0 |
| Stomatitis | 2 (22) | 0 |
| γ‐GT increased | 2 (22) | 0 |
| Hypocalcemia | 2 (22) | 0 |
| Oropharyngeal pain | 2 (22) | 0 |
Grades were evaluated based on Common Terminology Criteria for Adverse Events version 4.0. DRAE (any grade) with a frequency of ≥20% are presented. Patients were counted only once and categorized by the highest DRAE grade reported. No grade 4 or 5 AE were reported. DRAE (any grade) exhibited in a patient (n = 1): eye pain, photophobia, diarrhea, dyspepsia, gastritis, vomiting, adenoiditis, gingivitis, pericoronitis, hyperglycemia, hypoalbuminemia, limb discomfort, dizziness, dysgeusia, insomnia, cough, epistaxis, pharyngeal inflammation, pleuritic pain, pulmonary fibrosis, dry skin, pruritus, seborrheic dermatitis, skin disorder, skin hypopigmentation and urticaria. AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DRAE, drug‐related adverse event; γ‐GT, γ‐glutamyltransferase.